Glucose Monitoring After Liver Transplant and Transplant Outcomes
Studies blood sugar levels, tracked by sensor, in adults after liver transplant.
Key facts
- Who runs it
- Icahn School of Medicine at Mount Sinai
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Liver Transplant CGM
- Status
- Enrolling by invitation
- People taking part
- 40 people, planned
- Started
- 13 Oct 2025
- Expected to end
- 30 Dec 2027
- Type of study
- Observational
- Treatments tested
- Libre 3+
- Record updated
- 24 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a liver transplant and had a blood sugar above 180mg/dL (10 mmol/L) while in hospital. It follows their blood sugar with a sensor after they go home.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- People who had a liver transplant and a blood sugar above 180mg/dL (10 mmol/L) while in hospital.
- Earlier treatment
- Liver transplant. Those who also had a kidney or pancreas transplant at the same time cannot join.
- Biomarker or test result
- Blood sugar above 180mg/dL (10 mmol/L) at some point during the hospital stay.
Main reasons for not taking part
- Planned discharge to a rehabilitation or nursing facility
- A medical reason that prevents placing the glucose sensor
- Discharge expected more than 30 days after the transplant
- Kidney or pancreas transplant together with the liver transplant
This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL
Who cannot take part
- if discharge is anticipated to be >30 days post-transplant, or
- if recent transplant also included a kidney or pancreas transplant
- having a planned discharge to a rehabilitation or nursing facility,
- a contraindication to sensor placement,
Where in United States
- Mount Sinai HospitalNew York, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.
The group in the trial
- Participants post liver transplant
Participants who are discharged from after liver transplant.
Treatment: Libre 3+
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Post-discharge Glycemic Control After Liver Transplant and Impact on Transplant Outcomes
- Plain-language title
- Glucose Monitoring After Liver Transplant and Transplant OutcomesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 24 August 2026